Treatment of Helicobacter pylori infection in the presence of penicillin allergy

Table 1 Published studies of Helicobacter pylori eradication therapy in patients allergic to penicillin

Ref.	Yr	Country	Study type	Treatment details	n	Success rate (PP, %)	Success rate (ITT, %)
Prach et al[10]	1998	United Kingdom	Prospective,single cohort	1st line O 20 mg b.d., C 500 mg t.d.s, 14 ds	3	100;	100;
Gisbert et al[11]	2005	Spain	Prospective, single cohort	1st line O 20 mg b.d., C 500 mg b.d., M 400 mg b.d., 7 d; 2nd line RBC 400 mg b.d., T 500 mg q.d.s., M 250 mg q.d.s., 7 d; 3rd line O 20 mg b.d., C 500 mg b.d., RIF 150 mg b.d., 10 d; 4th line O 20 mg b.d., C 500 mg b.d., LF 500 mg b.d.,10 ds	12; 17; 9; 2	64; 53; 17; 100	58; 47; 11; 100
Rodriguez-Torres et al[12]	2005	Puerto Rico	Prospective, single cohort	1st line E 40 mg q.d.s., T 500 mg q.d.s., M 500 mg q.d.s.,10 d; 2nd line E 40 mg q.d.s., T 500 mg q.d.s., M 500 mg q.d.s.,10 d	17; 3	NA; NA	85; 100
Matsushima et al[13]	2006	Japan	Retrospective, single cohort	1st line PPI o.d., T 500 mg b.d., M 250 mg b.d., 7-14 d	5	100	80
Gisbert et al[14]	2010	Spain	Prospective, single cohort	1st line O 20 mg b.d., C 500 mg b.d., M 400 mg b.d., 7 d; 2nd line O 20 mg b.d., C 500 mg b.d., LF 500 mg b.d.,10 d	50; 15	55; 73	54; 73
Tay et al[15]	2012	Australia	Prospective, single cohort	2nd line R 20 mg t.d.s., B 240 mg q.d.s., RIF 150 mg b.d., CF 500 mg b.d., 10 d	69	94.2	94.2
Liang et al[16]	2013	China	Prospective, randomised	2nd line 109 pen allergic overall but results reported for whole group including non-allergic; L 30 mg b.d., B 220 mg b.d., T 500 mg t.d.s., F 100 mg t.d.s., 14 d; L 30 mg b.d., B 220 mg b.d., T 500 mg q.d.s., M 400 mg q.d.s., 14 d	108; 107	96.1; 93.1	91.7; 87.9
Furuta et al[17]	2014	Japan	Retrospective, single cohort	1st line PPI b.d., SF 100 mg b.d., M 250 mg b.d., 7 d; 1st line PPI b.d., SF 100 mg b.d., M 250 mg b.d., 14 d; 2nd Line PPI b.d., SF 100 mg b.d., M 250 mg b.d., 7 d; 2nd Line PPI b.d., SF 100 mg b.d., M 250 mg b.d., 14 d; 3rd Line PPI b.d., SF 100 mg b.d., M 250 mg b.d., 7 d; 3rd Line PPI b.d., SF 100 mg b.d., M 250 mg b.d., 14 d	7; 4; 9; 3; 3; 2	100; 100; 100; 100; 100; 100	100; 100; 100; 100; 100; 100
Gisbert et al[18]	2015	Spain	Prospective, single cohort	1st line O 20 mg b.d., C 500 mg b.d., M 400 mg b.d., 7 d; 2nd line O 20 mg b.d., B 120 mg q.d.s., T 500 mg q.d.s., M 500 mg t.d.s., 10 d; 3rd line O 20 mg b.d., C 500 mg b.d., LF 500 mg b.d.,10 d; 4th line O 20 mg b.d., C 500 mg b.d., RIF 150 mg b.d., 10 d; 3rd line O 20 mg b.d., C 500 mg b.d., RIF 150 mg b.d., 10 d; 4th line O 20 mg b.d., C 500 mg b.d., LF 500 mg b.d.,10 d; 2nd line O 20 mg b.d., C 500 mg b.d., LF 500 mg b.d.,10 d; 3rd line O 20 mg b.d., B 120 mg q.d.s., T 500 mg q.d.s., M 500 mg t.d.s., 10 d; 1st line O 20 mg b.d., B 120 mg q.d.s., T 500 mg q.d.s., M 500 mg t.d.s., 10 d; 2nd line O 20 mg b.d., C 500 mg b.d., LF 500 mg b.d.,10 d	112; 24; 3; 2; 7; 2; 50; 3; 50; 14	59; 38; 50; 0; 20; 100; 73; 100; 75; 64;	57; 37; 33; 50; 14; 100; 64; 100; 74; 64;
Mori et al[19]	2017	Japan	Prospective, single cohort	1st line E 20 mg b.d., SF 100 mg b.d., M 250 mg b.d.,10 d; 2nd line E 20 mg b.d., SF 100 mg b.d., M 250 mg b.d.,10 d; 3rd line E 20 mg b.d., SF 100 mg b.d., M 250 mg b.d.,10 d	33; 19; 5	100; 84.2; 40	100; 84.2; 40
Ono et al[20]	2017	Japan	Retrospective,single cohort	1st line PPI b.d., C 200 mg b.d., M 250 mg b.d., 7 d; 1st line V 20 mg b.d., C 200 mg b.d., M 250 mg b.d., 7 d; 1st line PPI b.d., SF 100 mg b.d., M 250 mg b.d., 7 d; 1st line V 20 mg b.d., SF 100 mg b.d., M 250 mg b.d., 7 d; 2nd line PPI b.d., C 200 mg b.d., M 250 mg b.d., 7 d; 2nd line V 20 mg b.d., C 200 mg b.d., M 250 mg b.d., 7 d; 2nd line PPI b.d., SF 100 mg b.d., M 250 mg b.d., 7 d; 2nd line V 20 mg b.d., SF 100 mg b.d., M 250 mg b.d., 7 d	10; 13; 20; 14; 3; 1; 24; 3	55.6; 92.3; 100; 100; 33.3; 100; 100; 66.7	50; 92.3; 100; 92.9; 33.3; 100; 100; 66.7
Sue et al[21]	2017	Japan	Prospective& retrospective, single cohort	1st line V 20 mg b.d., C 200 or 400 mg b.d., M 250 mg b.d., 7 d; 1st line PPI b.d, C 200 or 400 mg b.d, M 750 mg b.d., 7 d	20; 30	100; 86.2	100; 83.3
Osumi et al[22]	2017	Japan	Prospective, single cohort	1st line R 20 mg b.d, Mi 100 mg b.d, M 250 mg b.d., 7 d	5	100	100
Long et al[23]	2018	China	Prospective, randomised	1st line E 20 mg b.d., C 500 mg b.d., M 400 mg b.d., 14 d; 1st line E 20 mg b.d., B 600 mg b.d., C 500 mg b.d., M 400 mg b.d., 14 d	33; 33	70; 96	63.6; 84.8
Song et al[24]	2019	China	Prospective, single cohort	1st line E 20 mg b.d, B 220 mg b.d., LF 500 mg o.d., Cef 500 mg b.d., 14 d	152	90.1	85.5
Nyssen et al[25]	2020	Europe	Retrospective,multi-centre registry	1st line PPI, C, M; 1st line PPI, C, LF; 1st line PPI, B, T, M; 2nd line PPI, C, LF; 2nd line PPI, M, LF; 2nd line PPI, B, T, M; 3rd line PPI, B, T, M; 3rd line PPI, B, C, LF; 3rd line PPI, C, LF (NB drug dose, frequency and duration not specified)	285; 54; 250; 20; 13; 70; 18; 1; 2	69; 82; 92; 73.7; 76.5; 81.8; 77.8; 100; 50	69; 80; 91; 75; 76.5; 78.3; 77.8; 100; 50
Luo et al[26]	2020	China	Prospective, single cohort	1st & 2nd line E 20 mg b.d., C 500 mg b.d., M 400 mg b.d., 14 d; 1st & 2nd line E20 mg b.d., B 220 mg b.d., C 500 mg b.d., M 400 mg q.d.s., 14 d; 1st & 2nd line E 20 mg b.d., LF 500 mg o.d., M 400 mg b.d., 14 d; 1st & 2nd line E 20 mg b.d., B 220 mg b.d, LF 500 mg o.d., M 400 mg q.d.s., 14 d; 1st & 2nd line E 20 mg b.d., T 500 mg q.d.s., M 400 mg b.d., 14 d; 1st & 2nd line E 20 mg b.d., B 220 mg b.d, T 500 mg q.d.s., M 400 mg q.d.s., 14 d	5; 22; 1; 10; 2; 72	100; 94.1; 100; 100; 100; 100	100; 81.8; 100; 80; 100; 97.2
Sue et al[27]	2021	Japan	Prospective, single cohort	2nd line V 20 mg b.d,, SF 100 mg b.d., M 250 mg b.d., 7 d	17	88.2	88.2

PP: Per protocol analysis; ITT: Intention to treat analysis; B: Bismuth compound; C: Clarithromycin; Cef: Cefuroxime; CF: Ciprofloxacin; E: Esomeprazole F: Furazolidone; LF: Levofloxacin; M: Metronidazole; Mi: minocycline O: Omeprazole; PPI: proton pump inhibitor; R: Rabeprazole; RBC: ranitidine bismuth subcitrate; RIF: Rifabutin; SF: Sitafloxacin; T: Tetracycline; V: Vonoprazan.